Assembly Biosciences Q2 2024 Earnings Report

Assembly Biosciences EPS Results

• Actual EPS: -$1.98
• Consensus EPS: -$2.96
• Beat/Miss: Beat by +$0.98
• One Year Ago EPS: N/A

Assembly Biosciences Revenue Results

• Actual Revenue: $8.53 million
• Expected Revenue: $5.96 million
• Beat/Miss: Beat by +$2.57 million
• YoY Revenue Growth: N/A

Assembly Biosciences Announcement Details

• Quarter: Q2 2024
• Date: 8/8/2024
• Time: N/A

Assembly Biosciences (NASDAQ:ASMB), a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial. The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV). In addition, it develops an oral non-nucleoside polymerase inhibitor targeting transplant-related herpesviruses; and a small molecule interferon-a receptor agonist targeting HBV and HDV. The company has collaboration agreements with Gilead Sciences, Inc. and BeiGene, Ltd. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.